For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 5,814 | 9,643* | 14,391 | 21,196 |
| General and administrative | 5,138 | 4,797* | 4,775 | 5,880 |
| Total operating expenses | 10,952 | 14,439 | 19,166 | 27,076 |
| Loss from operations | -10,952 | -14,439* | -19,166 | -27,076 |
| Interest income | 164 | 715* | 342 | - |
| Change in fair value of warrant liability | -9,640 | -2,231* | -2,099 | - |
| Other expense, net | -26 | 3,846* | -2,011 | - |
| Total other income, net | 9,778 | 6,792* | 430 | - |
| Net loss and comprehensive loss | -1,174 | -7,647 | -18,736 | -26,700 |
| Basic EPS | -0.04 | -0.299 | -1.13 | -1.74 |
| Diluted EPS | -0.04 | -0.299 | -1.13 | -1.74 |
| Basic Average Shares | 28,671,819 | 25,534,584 | 16,635,784 | 15,333,962 |
| Diluted Average Shares | 28,671,819 | 25,534,584 | 16,635,784 | 15,333,962 |
Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc. (JSPR)